Casdin Capital, LLC Fate Therapeutics Inc Transaction History

Casdin Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $1.05 Million - $1.8 Million	-50,000 Reduced 2.38%	2,050,000 $45.9 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $23.1 Million - $55.1 Million	-1,300,000 Reduced 38.24%	2,100,000 $52 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $25.3 Million - $41.1 Million	350,000 Added 11.48%	3,400,000 $280 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $10.1 Million - $17.6 Million	500,000 Added 19.61%	3,050,000 $105 Million
Q3 2019 Nov 12, 2019	BUY	$15.47 - $22.5 $39.4 Million - $57.4 Million	2,550,000 New	2,550,000 $51.8 Billion
Q3 2019 Nov 12, 2019	SELL	$15.47 - $22.5 $39.4 Million - $57.4 Million	-2,550,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$8.75 - $16.29 $437,500 - $814,500	-50,000 Reduced 1.92%	2,550,000 $41.5 Million
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $8.08 Million - $13.6 Million	2,050,000 Added 372.73%	2,600,000 $15.9 Million
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $1.43 Million - $2.37 Million	550,000	550,000 $2.18 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.